Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Other Events

Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On December2, 2018, Syros Pharmaceuticals,Inc. issued a press release reporting initial data from its ongoing Phase 2 clinical trial assessing the safety and efficacy of SY-1425 in combination with azacitidine in newly diagnosed acute myeloid leukemia (“AML”) patients who are not suitable candidates for standard chemotherapy, and in combination with daratumumab in relapsed or refractory AML and higher-risk myelodysplastic syndrome patients. A copy of this press release is filed as Exhibit99.1 to this Form8-K and incorporated herein by reference. The information contained on websites referenced in this press release is not incorporated herein.

Item 9.01 Financial Statements and Exhibits.




Press release dated December2, 2018

Syros Pharmaceuticals, Inc. Exhibit
EX-99.1 2 a18-40969_1ex99d1.htm EX-99.1 Exhibit 99.1     Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting   SY-1425 in Combination with Azacitidine Shows 63% Overall Response Rate and Rapid Onset of Clinical Responses in RARA or IRF8 Biomarker-Positive Newly Diagnosed Unfit AML Patients   Initial Data from Biomarker-Positive and -Negative Azacitidine Combination Cohorts Support Potential Predictive Value of RARA and IRF8 Biomarkers for Patient Selection   SY-1425 Induced CD38 Expression in Majority of Patients in Daratumumab Combination Cohort in Relapsed/Refractory AML and Higher-Risk MDS Patients   Both Combinations Have Been Generally Well-Tolerated to Date   CAMBRIDGE,…
To view the full exhibit click here

About Syros Pharmaceuticals,Inc. (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

An ad to help with our costs